| abstract |
The present invention is in the area of gene therapy, in particular in the treatment and prevention of EBV-positive cancers by administering a nucleic acid molecule comprising an EBNA1-responsive promoter region operatively linked to a gene necessary for viral replication, preferably in adenovirus replication, and optionally one or more heterologous genes. In embodiments, the one or more heterologous genes comprise a therapeutic gene that can limit tumour cell growth and/or cause the tumour cell to die. |